- Amyloidosis is an ultra-rare metabolic disorder that affects the functionality and shape of organs and tissues. This can give rise to life threatening diseases. Amyloidosis generally develops when amyloid protein is deposited in the tissues and organs.
- The increasing demand for amyloidosis treatments is primarily driven by heightened disease awareness, advancements in diagnostic capabilities, and a growing patient population affected by both hereditary and wild-type forms of the disease. A surge in research and development activities is also contributing to improved therapeutic options and accessibility.
- North America is projected to lead the global amyloidosis treatment market, North America is expected to account for the largest revenue share of 40.01% in 2025. This dominance is supported by early adoption of novel therapeutics, higher healthcare spending, strong reimbursement structures, and the robust presence of major pharmaceutical players. The U.S., in particular, is witnessing significant growth due to the availability of approved therapies like tafamidis and the expansion of clinical trials.
- The Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, the Asia-Pacific region is driven by increasing urbanization, improving healthcare infrastructure, rising disposable incomes, and a growing focus on rare diseases. Countries such as China, Japan, and South Korea are investing heavily in early diagnosis and treatment access for amyloidosis.
- The tafamidis segment is expected to hold the largest market share of 43.2% in 2025, owing to its proven clinical efficacy, established safety profile, and status as the first FDA-approved treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM). Its oral administration route and effectiveness in delaying disease progression have made it the preferred therapeutic option among healthcare providers.
